Investors Eye Lead Role in ADMA Biologics Securities Class Action

The complaint alleges that ADMA Biologics misled the market by concealing critical operational flaws. According to the filing, the company allegedly engaged in undisclosed related-party transactions and utilized channel stuffing to artificially inflate reported revenue figures. These actions, coupled with what the lawsuit describes as a failure to maintain adequate internal controls, reportedly rendered the company’s public statements about its business trajectory materially false or lacking a reasonable basis.

Shareholders impacted by these developments have until August 10, 2026, to apply for the lead plaintiff position. While investors can choose to remain passive class members, those interested in actively participating in the litigation are directed to contact Charles Linehan at Glancy Prongay Wolke & Rotter LLP. The firm is managing inquiries via its Los Angeles office, emphasizing that the deadline is a firm threshold for those seeking to influence the direction of the legal proceedings.